- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4 - Errors in Genetic Testing
In this segment, Dr Berger asked about errors in test result interpretation, as well as the problem of inconsistent testing. Panelists showed concern with unregulated direct-to-consumer testing.
In this segment, Dr Berger asked about errors in test result interpretation, as well as the problem of inconsistent testing. Panelists showed concern with unregulated direct-to-consumer testing. Ms Matloff referred to a study from the Government Accountability Office that proved different tests lead to different results in the same study. Regarding future trends in genetic testing, Ms Matloff notes the increase of ovarian, pancreatic, and renal cell cancer genetic testing and research. Ms Nagy said that there will also be expansions in cardiovascular diseases and in neurology. As testing costs decrease, there will continue to be growth in testing research.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
